Last reviewed · How we verify

Atomoxetine 80 MG

Brigham and Women's Hospital · FDA-approved active Small molecule Quality 2/100

Atomoxetine 80 MG is a Small molecule drug developed by Brigham and Women's Hospital. It is currently FDA-approved. Also known as: Atomoxetine, Strattera.

Atomoxetine 80 MG, marketed by Brigham and Women's Hospital, is an established treatment in its class with a key composition patent expiring in 2028. The drug's primary strength lies in its well-established market presence and protected intellectual property. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic nameAtomoxetine 80 MG
Also known asAtomoxetine, Strattera
SponsorBrigham and Women's Hospital
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Atomoxetine 80 MG

What is Atomoxetine 80 MG?

Atomoxetine 80 MG is a Small molecule drug developed by Brigham and Women's Hospital.

Who makes Atomoxetine 80 MG?

Atomoxetine 80 MG is developed and marketed by Brigham and Women's Hospital (see full Brigham and Women's Hospital pipeline at /company/brigham-and-women-s-hospital).

Is Atomoxetine 80 MG also known as anything else?

Atomoxetine 80 MG is also known as Atomoxetine, Strattera.

What development phase is Atomoxetine 80 MG in?

Atomoxetine 80 MG is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing